[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"conversion-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:conversion-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636038","phase-2-ipilimumab-n01-combined-with-sintilimab-bevacizumab-biosimilar-and-hepatic-arterial-infusion-chemotherapy-as-conversion-therapy-for-unresectable-intermediate-advanced-hepatocellular-carcinoma-100636038",false,"NCT07560488","Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma","Conversion Therapy With Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma: A Prospective, Single-Arm Phase II Study","Inclusion Criteria:\n\n* Written informed consent must be signed prior to initiation of any study-related procedures;\n* Age ≥ 18 years, and ≤75 years, regardless of gender;\n* Clinically diagnosed or histologically\u002Fcytologically confirmed hepatocellular carcinoma (HCC) according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition);\n* No prior anti-tumor therapy for HCC before study treatment\n* Unresectable locally advanced or advanced HCC (CNLC Stage IIa-IIIb).\n* Expected overall survival \\> 6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Child-Pugh score class A or B\n* Adequate organ function defined by the following laboratory parameters:\n\n  1. Absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL without granulocyte colony-stimulating factor support within 14 days;\n  2. Platelet count ≥ 80×10⁹\u002FL without transfusion within 14 days;\n  3. Hemoglobin \\> 9 g\u002FdL without transfusion or erythropoietin within 14 days;\n  4. Total bilirubin ≤ 1.5×upper limit of normal (ULN); or total bilirubin \\> ULN with direct bilirubin ≤ ULN;\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN;\n  6. Serum creatinine ≤ 1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥ 60 mL\u002Fmin;\n  7. Adequate coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5×ULN;\n  8. Normal thyroid function defined as thyroid-stimulating hormone (TSH) within normal limits. Subjects with abnormal baseline TSH but normal total T3 (or FT3) and FT4 are also eligible;\n  9. Myocardial enzymes within normal limits; isolated laboratory abnormalities deemed clinically insignificant by the investigator are permitted.\n* Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study drug (Day 1 of Cycle 1). A blood pregnancy test is required if the urine test is inconclusive; They must agree to use adequate contraception during the study period and for 8 weeks after the last dose of study drug;\n* All subjects (male or female) of reproductive potential must use a highly effective contraceptive method with an annual failure rate \\\u003C 1% throughout treatment and for 120 days after the last dose of immunotherapy or 180 days after the last dose of chemotherapy, whichever is longer.\n\nExclusion Criteria:\n\n* Target disease exceptions:\n\n  1. Fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma.\n  2. Recurrent HCC.\n  3. Clinically diagnosed hepatic encephalopathy within the most recent 6 months.\n* Autoimmune hepatitis (requiring liver biopsy confirmation);\n* History of organ transplantation or history of hepatic encephalopathy;\n* Diffuse hepatocellular carcinoma;\n* Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage;\n* History of any renal disease or nephrotic syndrome.\n* Variceal bleeding (esophageal or gastric varices) due to portal hypertension within the past 6 months;severe (Grade 3) varices on endoscopy within 3 months before first dose;evidence of portal hypertension (e.g., splenomegaly \\>10 cm in longest diameter with platelets \\\u003C100×10⁹\u002FL on imaging) with high bleeding risk as assessed by the investigator;\n* Arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other severe thromboembolism.Excluded are catheter-related or port-related thrombosis or superficial venous thrombosis that is stable with standard anticoagulation;\n* Severe bleeding tendency or coagulopathy, or ongoing thrombolytic therapy;\n* Prophylactic low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is permitted; vitamin K antagonists (e.g., warfarin) are excluded;\n* Long-term use of anti-platelet agents including aspirin, dipyridamole, clopidogrel, or other similar medications;\n* Uncontrolled hypertension despite optimal medical management (systolic BP \\>140 mmHg or diastolic BP \\>90 mmHg); history of hypertensive crisis or hypertensive encephalopathy;\n* Symptomatic congestive heart failure (NYHA Class II-IV); symptomatic or poorly controlled arrhythmia; congenital long QT syndrome or QTcF \\>500 ms at screening;\n* History of gastrointestinal perforation and\u002For fistula within the past 6 months; history of bowel obstruction (including partial obstruction requiring parenteral nutrition); extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea;\n* Major surgical procedure (cranial, thoracic, or abdominal) within 4 weeks before first dose, or non-healing wounds, ulcers, or fractures.Core needle biopsy or minor surgery within 7 days before first dose is excluded, except for venous catheter placement for intravenous access;\n* History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction;\n* Acute or chronic active hepatitis B or C infection:HBV DNA \\>2000 IU\u002FmL or 10⁴ copies\u002FmL;HCV RNA \\>10³ copies\u002FmL;coinfection with HBsAg and anti-HCV antibody;\n* Active tuberculosis (TB), ongoing anti-TB treatment, or anti-TB treatment within 1 year before first dose;\n* Human immunodeficiency virus (HIV) infection (positive HIV 1\u002F2 antibody) or active syphilis;\n* Active or poorly controlled severe infection; severe infection requiring hospitalization (including sepsis, bacteremia, or severe pneumonia) within 4 weeks before first dose;\n* Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years before first dose.Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal\u002Fpituitary insufficiency) is permitted.History of primary immunodeficiency.Subjects with isolated positive autoimmune antibodies will be evaluated at the investigator's discretion;\n* Systemic immunosuppressive drugs within 4 weeks before first dose, excluding topical, inhaled, or intranasal corticosteroids or physiological systemic corticosteroids (≤10 mg\u002Fday prednisone or equivalent).Temporary corticosteroids for acute dyspnea in asthma or COPD are permitted;\n* Live attenuated vaccine within 4 weeks before first dose or planned use during the study period;\n* Chinese herbal medicine with anti-tumor indications, or immunomodulatory agents (including thymosin, interferon, interleukin) within 2 weeks before first dose, except for local administration for pleural effusion or ascites;\n* Uncontrolled or irreversible metabolic disorders, other acute or chronic non-malignant organ diseases, systemic illnesses, or paraneoplastic syndromes that may increase medical risk or confound survival assessment;\n* Diagnosis of another malignancy within 5 years before first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.For other malignancies diagnosed \\>5 years before enrollment, pathological or cytological confirmation of recurrent\u002Fmetastatic lesions is required;\n* Prior treatment with anti-PD-1, anti-PD-L1\u002FL2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors;\n* Known hypersensitivity to sintilimab, bevacizumab, ipilimumab N01 or their excipients, or severe hypersensitivity to other monoclonal antibodies;\n* Participation in another interventional clinical trial within 4 weeks before first dose;\n* Female subjects who are pregnant or breastfeeding;\n* Any other acute or chronic diseases, psychiatric disorders, or abnormal laboratory values that may increase risks associated with study participation or study drug administration, or interfere with the interpretation of study results, and that, in the investigator's judgment, render the patient ineligible for participation in this study.","ALL","18 Years","75 Years",{"count":20,"type":21},43,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Conversion therapy for unresectable intermediate-advanced hepatocellular carcinoma (uHCC) has evolved from systemic therapy to combined local-systemic approaches, but current regimens still have limited surgical conversion rates.\n\nThis prospective, single-arm phase II study evaluates a combination regimen of PD-1 inhibitor (sintilimab) plus CTLA-4 inhibitor (ipilimumab N01), bevacizumab biosimilar, and HAIC for patients with initially unresectable intermediate-advanced HCC. The primary goal is to achieve a higher surgical conversion rate with manageable safety",[27,28],"HCC - Hepatocellular Carcinoma","Conversion Therapy","RECRUITING","2026-04-27",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2026-03-30",{"date":37,"type":21},"2028-04",{"name":39,"class":40},"Tianjin Medical University Cancer Institute and Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100636153","phase-2-tislelizumab-plus-chemotherapy-and-bace-for-unresectable-nsclc-100636153","NCT07561983","Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC","Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)","BEACON-Lung","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n* Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system\n* Initially unresectable disease as determined by multidisciplinary team (MDT) assessment\n* At least 1 measurable intrapulmonary lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Forced expiratory volume in the first second (FEV1) \\> 1.0 L and \\> 40% of predicted normal value\n* Estimated life expectancy of at least 3 months\n* Adequate organ function\n* Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment\n* Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Ability to understand and willingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Prior local therapy for NSCLC, including radiotherapy or interventional therapy\n* Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations\n* Distant organ metastasis\n* History of another malignancy within the past 5 years\n* Active autoimmune disease or history of autoimmune disease requiring systemic treatment\n* Known allergy to any study drug or excipient\n* Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis\n* Major surgery requiring general anesthesia within 4 weeks before first dose\n* Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk\n* Participation in another interventional therapeutic clinical study\n* Psychiatric illness or history of psychotropic drug abuse that may compromise study participation\n* Any condition judged by the investigator to make the patient unsuitable for the study","80 Years",{"count":52,"type":21},39,[24],"The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:\n\n* What is the 1-year event-free survival (EFS) rate with this treatment?\n* Can this treatment improve tumor response and the chance of curative-intent resection?\n* What adverse events occur during treatment?\n\nParticipants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.",[56,57,58,59,28],"Unresectable Stage III Non-small Cell Lung Cancer","Tislelizumab","Chemotherapy","Chemoembolization, Therapeutic",[61,57,58,62,28],"Unresectable Non-Small Cell Lung Cancer","Bronchial Artery Chemoembolization","NOT_YET_RECRUITING","2026-04-24",{"date":32,"type":33},{"date":32,"type":21},{"date":68,"type":21},"2028-12-31",{"name":70,"class":40},"Sichuan Cancer Hospital and Research Institute",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":41},"100608974","a-randomized-trial-of-surgical-decision-making-guided-by-tdtp-recist-100608974","NCT07208526","A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST","A Multicenter Randomized Controlled Study on Surgical Decision-Making Guided by the TDTP-RECIST Evaluation System for Locally Advanced Intrahepatic Cholangiocarcinoma Following GOLP Conversion Therapy","Inclusion Criteria:\n\n\\-\n\nSubjects eligible to participate in this study must meet all of the following criteria:\n\n1. Male or female aged 18-75 years;\n2. Patients must provide signed informed consent prior to enrollment, demonstrating the ability to understand and willingness to sign the written informed consent form;\n3. Pathologically confirmed diagnosis of intrahepatic cholangiocarcinoma;\n4. Locally advanced disease, failure to achieve R0 resection, and absence of distant metastasis;\n5. At least one measurable lesion;\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0;\n7. Child-Pugh class A liver function;\n\nExclusion Criteria:\n\n\\-\n\nSubjects who meet any of the following exclusion criteria are not permitted to enroll in this study:\n\n1. Pathologically diagnosed hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, or other non-cholangiocarcinoma malignant components;\n2. Patients with postoperative recurrence, or those who have previously received PD-1\u002FPD-L1 antibodies, CTLA-4 antibodies, lenvatinib, or chemotherapy;\n3. History or current diagnosis of other malignancies;\n4. Active tuberculosis infection;\n5. Active, known, or suspected autoimmune disease;\n6. History of interstitial lung disease, or non-infectious pneumonitis requiring steroid treatment;\n7. Significant clinically significant bleeding symptoms within 3 months prior to enrollment, or clear bleeding tendency;\n8. Suspected allergy to the investigational drug(s).",{"count":79,"type":21},270,[81],"NA","This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy. Participants will be randomized at a 1:2:2 ratio into three arms: Control Arm (continued medication), Direct Surgery Arm, and TDTP-RECIST Assessment Arm. The primary endpoint is Overall Survival (OS).",[84,28,85,86],"Intrahepatic Cholangiocarcinoma (Icc)","TDTP-RECIST","GOLP Regimen","2025-09-28",{"date":89,"type":33},"2025-10-06",{"date":91,"type":21},"2025-12-01",{"date":68,"type":21},{"name":94,"class":40},"Shanghai Zhongshan Hospital"]